The approval of orforglipron in 2025 introduced the first oral non-peptide GLP-1 receptor agonist to the research landscape. For researchers... Continue reading
Semaglutide, tirzepatide, retatrutide, and orforglipron are all GLP-1R agonists — but they differ significantly in receptor selectivity, molecular class, route... Continue reading
Recombinant HGH and GH secretagogues both raise circulating growth hormone — but through fundamentally different mechanisms with distinct implications for... Continue reading
Semax and Selank are the two most research-documented nootropic peptides — both developed in Russia, both with regulatory approval in... Continue reading
The incretin agonist class has expanded rapidly — from GLP-1 monotherapy (semaglutide) to dual GIP/GLP-1 agonism (tirzepatide) to triple GIP/GLP-1/glucagon... Continue reading
Ipamorelin, GHRP-2, and GHRP-6 are all ghrelin receptor (GHSR-1a) agonists that stimulate pulsatile GH release from the anterior pituitary. Their... Continue reading
